PROCEPT BioRobotics Past Earnings Performance
Past criteria checks 0/6
PROCEPT BioRobotics's earnings have been declining at an average annual rate of -20.9%, while the Medical Equipment industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 56.4% per year.
Key information
-20.9%
Earnings growth rate
63.3%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 56.4% |
| Return on equity | -41.5% |
| Net Margin | -50.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102
Oct 31
Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth
Sep 12Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval
Aug 27Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%
Aug 25Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results
Aug 04PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce
May 21The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Apr 05US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results
Mar 01Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt
Feb 07Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher
Dec 14Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?
Feb 27Procept Biorobotics announces $52M debt refinancing
Oct 10Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems
Sep 19Procept BioRobotics Has Resources To Ramp Up Commercialization
Sep 01Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment
May 26Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues
May 10Revenue & Expenses Breakdown
How PROCEPT BioRobotics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 200 | -100 | 159 | 62 |
| 30 Jun 24 | 177 | -104 | 150 | 57 |
| 31 Mar 24 | 156 | -103 | 141 | 51 |
| 31 Dec 23 | 136 | -106 | 132 | 48 |
| 30 Sep 23 | 116 | -107 | 121 | 44 |
| 30 Jun 23 | 102 | -105 | 113 | 40 |
| 31 Mar 23 | 85 | -98 | 101 | 35 |
| 31 Dec 22 | 75 | -87 | 89 | 29 |
| 30 Sep 22 | 61 | -77 | 79 | 24 |
| 30 Jun 22 | 50 | -69 | 66 | 22 |
| 31 Mar 22 | 41 | -64 | 59 | 19 |
| 31 Dec 21 | 34 | -60 | 51 | 19 |
| 30 Sep 21 | 28 | -57 | 44 | 18 |
| 30 Jun 21 | 21 | -55 | 39 | 17 |
| 31 Mar 21 | 14 | -53 | 34 | 17 |
| 31 Dec 20 | 8 | -53 | 30 | 16 |
| 31 Dec 19 | 6 | -42 | 29 | 13 |
Quality Earnings: PRCT is currently unprofitable.
Growing Profit Margin: PRCT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRCT is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.
Accelerating Growth: Unable to compare PRCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRCT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).
Return on Equity
High ROE: PRCT has a negative Return on Equity (-41.48%), as it is currently unprofitable.